Project Grant K99CA312809
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $170K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $110,190 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), effective December 27, 2025 through June 30, 2028. The award supports biomedical training and research development in cancer biology, specifically focused on unraveling the mechanisms of neoantigen vaccine-induced epitope spreading (ES)—a phenomenon in which vaccine-primed tumor cell destruction...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $170,641 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) for the period August 1, 2025 through July 31, 2027. The award supports research training and investigator development focused on advancing understanding of tumor-immune interactions in colorectal cancer through multimodal spatial profiling analysis. The project will utilize highly multiplexed...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Dana-Farber Cancer Institute, Inc. a Project Grant of $718,275 under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031. This award supports fundamental research investigating context-specific pathway dependencies of nuclear envelope (NE) proteins in brain cancer. The research employs a large-scale analysis framework called WEBSTER to assess how NE-associated proteins...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $645,102 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026, through June 30, 2031. The award funds fundamental research investigating the molecular mechanisms governing WEE1 kinase's transition between functioning as a cell cycle checkpoint enzyme and as a phosphorylation substrate. The research addresses a critical gap in cell cycle...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.71 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through July 31, 2032. The award supports research into new approaches to targeting cell cycle proteins for cancer treatment, specifically addressing limitations of current cyclin-dependent kinase (CDK) inhibitors. The project focuses on three critical therapeutic...
- Federal Grant Award Summary Dana-Farber Cancer Institute received a $151,040 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) awarded on December 23, 2025, with a completion date of September 14, 2027. This award supports postdoctoral research training and investigation into the structural mechanisms of oligomeric BAK (BAKO), a pro-apoptotic protein in the BCL-2 family. The research aims to elucidate how full-length BAK self-associates and...
- Federal Grant Award Summary The National Cancer Institute awarded $275,990 to Dana-Farber Cancer Institute, Inc. under the Cancer Research Manpower program (CFDA 93.398) on September 2, 2025, for research extending through August 31, 2026. This Project Grant supports the development of engineered living materials (ELMs) as programmable therapeutic implants for pancreatic ductal adenocarcinoma (PDAC), a cancer with a 5-year survival rate below 5%. The award funds two primary research aims: (1)...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $737,086 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026 through June 30, 2031. The award supports translational research to identify and validate novel therapeutic targets for translocation renal cell carcinoma (TRCC), an aggressive cancer subtype currently lacking approved targeted therapies. The research delivers two primary products:...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Dana-Farber Cancer Institute, Inc. a Project Grant of $159,304 under the Cancer Research Manpower program (CFDA 93.398) for the period July 1, 2025 through June 30, 2027. This award supports research training and investigator development focused on identifying signaling pathways that govern tumoricidal macrophage function in pancreatic cancer. The project aims to elucidate receptor-ligand interactions that enable...
- Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $134,919 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) on June 11, 2026, with a completion date of May 31, 2028. The award funds biomedical research training and workforce development focused on structure-function and mechanistic studies of a glycosyltransferase complex (POMT) in fusion-driven pediatric gliomas. The institute will deliver research services including...